Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 13/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | BIRC3 | Q13489 | 5/20 | 0.50 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2212272 | 1.00 | XIAP (0.64) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL18494245 | 0.91 | XIAP (0.62) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL2209958 | 0.91 | XIAP (0.62) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL2209986 | 0.91 | XIAP (0.62) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL2245299 | 0.90 | XIAP (0.61) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL2213354 | 0.90 | XIAP (0.60) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL2211937 | 0.90 | XIAP (0.60) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL2212223 | 0.88 | XIAP (0.61) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL2211890 | 0.88 | XIAP (0.61) | XIAPTSHRHPGDBIRC3BIRC2 | |
| SCHEMBL2211136 | 0.87 | XIAP (0.57) | XIAPTSHRHPGDBIRC3BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | XIAP 1/4885TSHR 4823/4885HPGD 2286/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | XIAP 1/4885TSHR 4823/4885HPGD 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.